Christopher Cabell
Director, Pulmatrix, Inc.
Companies
- Inhibikase Therapeutics, Inc.President Feb 25, 2025 to now1
- Zura Bio LtdEVP and CMO Mar 21, 2023 to May 22, 20232
- Pulmatrix, Inc.Board member Jun 25, 2020 to Jan 30, 20233
- Arena PharmaceuticalsEVP, Head of R&D, and CMO Jun 16, 2020 to Nov 30, 20204
Holdings
Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.
Shares held
- Inhibikase Therapeutics, Inc. IKT676,564 shares5$1.2M at $1.83Feb 21, 2026
- Zura Bio Ltd ZURA162,060 shares6$697.7K at $4.30May 18, 2023
As of each latest filing. The line shows shares held over time.
Recent filings
- Feb 21, 2026Returned to company 338,282 shares of Inhibikase Therapeutics, Inc.5
- May 18, 2023Granted 162,060 shares of Zura Bio Ltd6
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2SEC EDGARZura Bio Ltd, EVP and CMO
- 3SEC EDGARPulmatrix, Inc., Board member
- 4
- 5
- 6